Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

HYTRIN

TERAZOSIN HYDROCHLORIDE

Standard Dose
EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview HYTRIN is listed in Drugs@FDA under application 020347 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient TERAZOSIN HYDROCHLORIDE Form and strength CAPSULE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBOTT Submission history Latest submission status date: 2006-02-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview HYTRIN is listed in Drugs@FDA under application 020347 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TERAZOSIN HYDROCHLORIDE Form and strength CAPSULE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBOTT Submission history Latest submission status date: 2006-02-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
HYTRIN (TERAZOSIN HYDROCHLORIDE) | Drug Monograph | MedicHelpline